Contact Us 888-901-2226
Donate Now

Latest News

Bladder Cancer Advocacy Network Celebrates 15 Years of Helping Bladder Cancer Patients

(January 6, 2020, Bethesda, MD)  Today, the Bladder Cancer Advocacy Network (BCAN) announced that they have achieved another major milestone and are marking their 15th anniversary in 2020, representing 15 years of progress against bladder cancer.  Founded in 2005, BCAN is the only national advocacy organization devoted to advancing bladder

Read More

Announcing BCAN 2020 Young Investigator Awards

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards *(YIA), to support the development of outstanding early career research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer research.

Read More

FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV

Yesterday, the U.S. Food and Drug Administration announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV™ for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant)

Read More

Bladder Cancer Advocacy Network Sends Best Wishes to NBA Great Bob Lanier

The Bladder Cancer Advocacy Network, or BCAN, sends its well wishes to NBA great Bob Lanier, who is battling bladder cancer.   Mr. Lanier played for the Detroit Pistons and Milwaukee Bucks of the National Basketball Association. and was  inducted into the Naismith Memorial Basketball Hall of Fame in 1992. Mr.

Read More

2020 Bladder Cancer Research Innovation Award

December 4, 2019 | BCAN is pleased to announce the 2020 Bladder Cancer Research Innovation Award to support the work of an investigator with an exceptionally novel and creative project with great potential to produce breakthroughs in our understanding of the management of bladder cancer. One proposal will be funded

Read More

Event: Examining the Use of Checkpoint Inhibitors in Bladder Cancer

Examining the Use of Checkpoint Inhibitors in Bladder Cancer Thursday, December 5, 2019 Renaissance Capital Ballroom Washington, DC More information and registration Speakers Robert Dreicer, MD, MS, MACP, FASCO University of Virginia School of Medicine Charlottesville, Virginia Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director

Read More

The Bladder Cancer Advocacy Network Sends Well Wishes to New York State Senator James Seward

(November 7, 2019, Bethesda, Maryland) The Bladder Cancer Advocacy Network was saddened to learn of State Senator James Seward’s (NY-51) recurrence of bladder cancer, announced yesterday.  Senator Seward was first diagnosed in 2016. “We send our best wishes to Senator Seward and his family for a speedy and complete recovery,”

Read More

Meet the Kansas City Walk to End Bladder Cancer Ambassadors

Read More

BCAN Earns Coveted 4-Star Charity Navigator Ranking for Fifth Consecutive Year

October 17, 2019, Bethesda, Maryland – The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.  BCAN has earned this top distinction in each of the last five years, putting it

Read More

World Bladder Cancer Patient Coalition Appoints First Executive Director

October 1, 2019, Brussels – Today, the World Bladder Cancer Patient Coalition announced the appointment of Alex Filicevas as the organization’s first Executive Director. Alex comes from the largest cancer patient umbrella organization in Europe, the European Cancer Patient Coalition, where he led advocacy and policy initiatives, capacity building and

Read More

We have moved!

Please make note of BCAN's new address:

4520 East West Highway
Suite 610
Bethesda, MD 20814

Our phone numbers, (1-888-901-2226 and 301-215-9099),

remain the same.